The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Residual Complexes Containing SMARCA2 (BRM) Underlie the Oncogenic Drive of SMARCA4 (BRG1) Mutation
Open accessAbstract
Collectively, genes encoding subunits of the SWI/SNF (BAF) chromatin remodeling complex are mutated in 20% of all human cancers, with the SMARCA4 (BRG1) subunit being one of the most frequently mutated. The SWI/SNF complex modulates chromatin remodeling through the activity of two mutually exclusive catalytic subunits, SMARCA4 and SMARCA2 (BRM). Here, we show that a SMARCA2-containing residual SWI/SNF complex underlies the oncogenic activity of SMARCA4 mutant cancers. We demonstrate that a residual SWI/SNF complex exists in SMARCA4 mutant cell lines and plays essential roles in cellular proliferation. Further, using data from loss-of-function screening of 165 cancer cell lines, we identify SMARCA2 as an essential gene in SMARCA4 mutant cancer cell lines. Mechanistically, we reveal that Smarca4 inactivation leads to greater incorporation of the nonessential SMARCA2 subunit into the SWI/SNF complex. Collectively, these results reveal a role for SMARCA2 in oncogenesis caused by SMARCA4 loss and identify the ATPase and bromodomain-containing SMARCA2 as a potential therapeutic target in these cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Selective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262 · cited 1×
“Bromodomains have recently emerged as particularly good targets for anticancer therapy (50).”
BackgroundA landscape of driver mutations in melanoma
Hodis, E., Watson, I. R., Kryukov, G. V., Arold, S. T., Imielinski, M., Theurillat, J.-P., Nickerson, E., Auclair, D., Li, L., Place, C., et al. (2012) · Cell · doi:10.1016/j.cell.2012.06.024 · Cited by 2,610
Shain, A. H., Giacomini, C. P., Matsukuma, K., Karikari, C. A., Bashyam, M. D., Hidalgo, M., Maitra, A., & Pollack, J. R. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1114817109 · Cited by 221
Tolstorukov, M. Y., Sansam, C. G., Lu, P., Koellhoffer, E. C., Helming, K. C., Alver, B. H., Tillman, E. J., Evans, J. A., Wilson, B. G., Park, P. J., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1302209110 · Cited by 190
Self-citation
Cited by
Defining a Cancer Dependency Map
Tsherniak, A., Vazquez, F., Montgomery, P. G., Weir, B. A., Kryukov, G., Cowley, G. S., Gill, S., Harrington, W. F., Pantel, S., Krill-Burger, J. M., et al. (2017) · Cell · doi:10.1016/j.cell.2017.06.010 · Cited by 3,276
Self-citationBAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design
Farnaby, W., Koegl, M., Roy, M. J., Whitworth, C., Diers, E., Trainor, N., Zollman, D., Steurer, S., Karolyi-Oezguer, J., Riedmueller, C., et al. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0294-6 · Cited by 562
Genetics and biology of pancreatic ductal adenocarcinoma
Ying, H., Dey, P., Yao, W., Kimmelman, A. C., Draetta, G. F., Maitra, A., & DePinho, R. A. (2016) · Genes & Development · doi:10.1101/gad.275776.115 · Cited by 527
Witkowski, L., Carrot-Zhang, J., Albrecht, S., Fahiminiya, S., Hamel, N., Tomiak, E., Grynspan, D., Saloustros, E., Nadaf, J., Rivera, B., et al. (2014) · Nature Genetics · doi:10.1038/ng.2931 · Cited by 501
Synthetic lethality as an engine for cancer drug target discovery
Huang, A., Garraway, L. A., Ashworth, A., & Weber, B. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0046-z · Cited by 469
The present and future of the Cancer Dependency Map
Arafeh, R., Shibue, T., Dempster, J. M., Hahn, W. C., & Vazquez, F. (2025) · Nature Reviews Cancer · doi:10.1038/s41568-024-00763-x · Cited by 454
Self-citationSynthetic lethal therapies for cancer: what’s next after PARP inhibitors?
Ashworth, A., & Lord, C. J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0055-6 · Cited by 420
The Many Roles of BAF (mSWI/SNF) and PBAF Complexes in Cancer
Hodges, C., Kirkland, J. G., & Crabtree, G. R. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026930 · Cited by 414
Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer
Mohammad, H. P., Barbash, O., & Creasy, C. L. (2019) · Nature Medicine · doi:10.1038/s41591-019-0376-8 · Cited by 413
Cowley, G. S., Weir, B. A., Vazquez, F., Tamayo, P., Scott, J. A., Rusin, S., East-Seletsky, A., Ali, L. D., Gerath, W. F., Pantel, S. E., et al. (2014) · Scientific Data · doi:10.1038/sdata.2014.35 · Cited by 387
Self-citationRamos, P., Karnezis, A. N., Craig, D. W., Sekulic, A., Russell, M. L., Hendricks, W. P. D., Corneveaux, J. J., Barrett, M. T., Shumansky, K., Yang, Y., et al. (2014) · Nature Genetics · doi:10.1038/ng.2928 · Cited by 387
Le Loarer, F., Watson, S., Pierron, G., de Montpreville, V. T., Ballet, S., Firmin, N., Auguste, A., Pissaloux, D., Boyault, S., Paindavoine, S., et al. (2015) · Nature Genetics · doi:10.1038/ng.3399 · Cited by 378
A machine learning approach to integrate big data for precision medicine in acute myeloid leukemia
Lee, S.-I., Celik, S., Logsdon, B. A., Lundberg, S. M., Martins, T. J., Oehler, V. G., Estey, E. H., Miller, C. P., Chien, S., Dai, J., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02465-5 · Cited by 327
Vulnerabilities of Mutant SWI/SNF Complexes in Cancer
Helming, K. C., Wang, X., & Roberts, C. W. M. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.07.018 · Cited by 303
Self-citationThe disparate origins of ovarian cancers: pathogenesis and prevention strategies
Karnezis, A. N., Cho, K. R., Gilks, C. B., Pearce, C. L., & Huntsman, D. G. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.113 · Cited by 300
Marked for death: Targeting epigenetic changes in cancer
Pfister, S. X., & Ashworth, A. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.256 · Cited by 288
Vangamudi, B., Paul, T. A., Shah, P. K., Kost-Alimova, M., Nottebaum, L., Shi, X., Zhan, Y., Leo, E., Mahadeshwar, H. S., Protopopov, A., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3798 · Cited by 281
“2F) indicative of compensation, a finding that supports the reciprocal assembly and stability of SMARCA2 and SMARCA4 into the SWI/SNF complex (22).”
Papillon, J. P. N., Nakajima, K., Adair, C. D., Hempel, J., Jouk, A. O., Karki, R. G., Mathieu, S., Möbitz, H., Ntaganda, R., Smith, T., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01318 · Cited by 244
Self-citationCollateral lethality: a new therapeutic strategy in oncology
Muller, F. L., Aquilanti, E. A., & DePinho, R. A. (2015) · Trends in Cancer · doi:10.1016/j.trecan.2015.10.002 · Cited by 132
A SWI/SNF-specific Ig-like domain, SWIFT, is a transcription factor binding platform
Jain, S. U., Williamson, K. E., Ying, A. W., Turner, A. M., Jiang, R. J., Raval, S., So, K., Allison, M. J., Sankar, A., Sáme Guerra, D. D., et al. (2026) · Science · doi:10.1126/science.aeb3627 · Cited by 11
Metadata
- Authors
- Wilson, B. G., Helming, K. C., Wang, X., Kim, Y., Vazquez, F., Jagani, Z., Hahn, W. C., & Roberts, C. W. M.
- Venue
- Molecular and Cellular Biology
- Publisher
- Informa UK Limited
- Published
- 2014-03-01
- Volume
- 34
- Issue
- 6
- Pages
- 1136-1144
- ISSN
- 0270-7306 (ISSN-L)
- 1098-5549
- OpenAlex
- W2107829555
- Cited by
- 237
- References
- 4
- FWCI
- 8.52
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.